A new therapeutic approach tested in patients with heart failure and reduced left ventricular function shows encouraging results. Intravenous injection of umbilical cord-derived stem cells, administered three times at six-week intervals, proved to be safe and may improve right ventricular function. These cells, known for their reparative properties, primarily act by releasing substances that promote the formation of new blood vessels and protect the heart muscle.<\/p>\n
The study involved forty patients followed for one year. No serious adverse effects directly related to the treatment were observed. However, treated patients exhibited a temporary increase in a blood marker related to coagulation, suggesting an increased risk of clot formation. This change did not lead to major complications but could explain the lack of significant improvement in left ventricular function, contrary to expectations.<\/p>\n
On the other hand, right ventricular volumes improved notably in patients who received the stem cells compared to those on placebo. This result is particularly interesting because there are currently few specific treatments targeting this part of the heart. Researchers emphasize that the injected cells first pass through the right ventricle and lungs before reaching the left ventricle, which may explain their more pronounced effect in this area.<\/p>\n
All participants received the recommended treatments for heart failure, making the additional impact of stem cells on the right ventricle even more remarkable. Although this study does not yet allow conclusions about overall improvement in survival or quality of life, it opens a promising avenue for future research. The repeated use of these cells, harvested non-invasively and with low immunogenicity, could represent a breakthrough for patients with limited therapeutic options. The next steps will involve confirming these results in larger trials and evaluating the benefit of combining anticoagulant treatment to optimize the benefits.<\/p>\n
DOI:<\/strong> https:\/\/doi.org\/10.1038\/s41392-026-02678-5<\/a><\/p>\n Title:<\/strong> PRIME-HFrEF Trial: a randomized, double-blind, multi-dose umbilical cord-derived mesenchymal stem cell regimen for heart failure<\/p>\n Journal:<\/strong> Signal Transduction and Targeted Therapy<\/p>\n Publisher:<\/strong> Springer Science and Business Media LLC<\/p>\n Authors:<\/strong> Wei Han; Yuheng Jiao; Wei Chen; Xin Gong; Hao Hu; Yuanfeng Xin; Sibin Guan; Jun Zhao; Qi Zhang; Bing Yang; Jingwei Pan; Haiyan Wang; Qing Lu; Shuguang Chu; Dihui Cai; Liang Zheng; Wenwen Jia; Zhiying He; Huangtian Yang; Yi Eve Sun; Zhongmin Liu<\/p>\n","protected":false},"excerpt":{"rendered":" Do Umbilical Cord Stem Cells Improve Cardiac Function in Heart Failure Patients? A new therapeutic approach tested in patients with heart failure and reduced left ventricular function shows encouraging results. Intravenous injection of umbilical cord-derived stem cells, administered three times at six-week intervals, proved to be safe and may improve right ventricular function. These cells,… Continue reading Do Umbilical Cord Stem Cells Improve Cardiac Function in Heart Failure Patients?<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2,7],"tags":[],"class_list":["post-49","post","type-post","status-publish","format-standard","hentry","category-health","category-justice-law","entry"],"_links":{"self":[{"href":"https:\/\/themedicinereview.com\/en\/wp-json\/wp\/v2\/posts\/49","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/themedicinereview.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/themedicinereview.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/themedicinereview.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/themedicinereview.com\/en\/wp-json\/wp\/v2\/comments?post=49"}],"version-history":[{"count":1,"href":"https:\/\/themedicinereview.com\/en\/wp-json\/wp\/v2\/posts\/49\/revisions"}],"predecessor-version":[{"id":50,"href":"https:\/\/themedicinereview.com\/en\/wp-json\/wp\/v2\/posts\/49\/revisions\/50"}],"wp:attachment":[{"href":"https:\/\/themedicinereview.com\/en\/wp-json\/wp\/v2\/media?parent=49"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/themedicinereview.com\/en\/wp-json\/wp\/v2\/categories?post=49"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/themedicinereview.com\/en\/wp-json\/wp\/v2\/tags?post=49"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}